Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
AstraZeneca
This is a Phase I, randomised, single-blind, placebo-controlled study. The healthy Japanese participants will receive randomly (3:1) either AZD7503 or placebo subcutaneously. The study will comprise of: * A screening period of 28 days. * Randomization on Day 1. * A 9-week Treatment Period. Dose 1 will be administered on Day 1. Dose 2 will be administered at the study site on Day 29. Dose 3 will be administered on Day 57. * A follow-up period of 10 week after last dose of study intervention. * The total duration of the study will be 23 weeks
Age
18–60
Sex
ALL
Healthy volunteers
Accepted